AGIO — Agios Pharmaceuticals, Inc.
Is AGIO overbought or oversold? Here is the current MarketMoodz read.
Agios Pharmaceuticals, Inc. (AGIO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $29.89. The rating moved from Neutral to Oversold on November 17, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$29.89
- Last changeMoved from Neutral to Oversold on November 17, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Agios Pharmaceuticals, Inc. (AGIO) combines a targeted oncology/specialty pipeline with existing commercial activities and partner support. The near‑term outlook is catalyst‑driven: positive clinical readouts or partnership news could produce meaningful upside, while clinical, regulatory, or execution setbacks would be deleterious. The balance sheet appears sufficient to fund operations into upcoming milestones, mitigating immediate dilution risk, but financing needs remain a medium‑term consideration. In the current measured risk‑on market, selective interest in growth/specialty biotech could provide windows for appreciation; downside is concentrated around binary trial outcomes, reimbursement dynamics, and competitive pressure.
Key factors
- Near‑term clinical and regulatory catalysts from late‑stage and mid‑stage pipeline assets that can drive binary re‑rating on positive readouts
- Commercial revenue trajectory and execution for any approved products (supporting recurring cash inflows versus pure R&D burn)
- Healthy balance sheet / cash runway sufficient to fund operations into upcoming catalysts (reduces near‑term dilution risk)
- Partnerships and licensing arrangements with larger pharma that derisk development costs and provide validation
- Sector backdrop: measured risk‑on market tone and ongoing large‑cap pharma consolidation may support M&A interest in specialty franchises
Risks
- Clinical trial failures or unexpected safety/regulatory actions for key pipeline assets that would materially reduce valuation
- Revenue and reimbursement pressure from payors, pricing reforms, or lower-than-expected commercial uptake for approved products
- Need for additional capital if cash burn accelerates or commercial launch costs exceed forecasts, leading to share dilution
- Competitive dynamics from larger pharma or novel modalities that could erode market share for targeted indications
- Execution risk across manufacturing, commercialization, and partnering milestones that could delay value realization
See today's live rating, score and targets
Members see the live hourly rating for AGIO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.